Avantor, Inc. (NYSE:AVTR) Position Lifted by Robeco Schweiz AG

Robeco Schweiz AG lifted its stake in Avantor, Inc. (NYSE:AVTR - Free Report) by 8.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,288,920 shares of the company's stock after acquiring an additional 676,365 shares during the period. Avantor makes up about 3.3% of Robeco Schweiz AG's holdings, making the stock its 2nd largest holding. Robeco Schweiz AG owned 1.22% of Avantor worth $134,363,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Avantor by 10.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,257 shares of the company's stock worth $132,000 after acquiring an additional 592 shares during the last quarter. American Trust raised its position in Avantor by 4.5% in the 4th quarter. American Trust now owns 15,198 shares of the company's stock worth $320,000 after purchasing an additional 658 shares during the period. Smartleaf Asset Management LLC lifted its stake in Avantor by 106.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,611 shares of the company's stock worth $34,000 after purchasing an additional 830 shares during the last quarter. Nissay Asset Management Corp Japan ADV increased its holdings in shares of Avantor by 1.0% in the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 82,523 shares of the company's stock worth $1,767,000 after buying an additional 857 shares during the period. Finally, Portside Wealth Group LLC lifted its position in Avantor by 9.0% in the first quarter. Portside Wealth Group LLC now owns 10,673 shares of the company's stock valued at $173,000 after purchasing an additional 882 shares during the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

AVTR has been the topic of a number of research analyst reports. Robert W. Baird reduced their price target on Avantor from $21.00 to $17.00 and set an "outperform" rating on the stock in a report on Monday, April 28th. Barclays decreased their target price on shares of Avantor from $18.00 to $15.00 and set an "overweight" rating for the company in a research note on Monday, April 28th. Morgan Stanley cut Avantor from an "overweight" rating to an "equal weight" rating in a research report on Tuesday, April 29th. Wells Fargo & Company reduced their price objective on Avantor from $25.00 to $22.00 and set an "overweight" rating for the company in a research report on Thursday, April 17th. Finally, The Goldman Sachs Group cut Avantor from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $23.00 to $14.00 in a research note on Tuesday, April 29th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $18.14.

Insider Activity

In related news, Director Joseph R. Massaro acquired 8,100 shares of Avantor stock in a transaction on Tuesday, April 29th. The shares were bought at an average cost of $12.30 per share, with a total value of $99,630.00. Following the completion of the purchase, the director directly owned 35,038 shares of the company's stock, valued at $430,967.40. The trade was a 30.07% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Gregory L. Summe bought 30,000 shares of the company's stock in a transaction dated Friday, May 23rd. The stock was bought at an average price of $12.50 per share, with a total value of $375,000.00. Following the acquisition, the director owned 100,000 shares in the company, valued at approximately $1,250,000. This trade represents a 42.86% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 83,100 shares of company stock worth $1,027,630 over the last 90 days. Corporate insiders own 1.20% of the company's stock.

Avantor Price Performance

Shares of Avantor stock traded down $0.37 during trading on Monday, reaching $13.22. 13,022,007 shares of the stock traded hands, compared to its average volume of 9,962,400. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.12 and a quick ratio of 0.75. The company has a market capitalization of $9.01 billion, a price-to-earnings ratio of 12.71, a P/E/G ratio of 1.44 and a beta of 1.05. Avantor, Inc. has a 52-week low of $11.82 and a 52-week high of $28.00. The business has a fifty day simple moving average of $13.21 and a two-hundred day simple moving average of $16.28.

Avantor (NYSE:AVTR - Get Free Report) last released its quarterly earnings data on Friday, April 25th. The company reported $0.23 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.23. The business had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.61 billion. Avantor had a return on equity of 11.93% and a net margin of 10.70%. The company's revenue was down 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.22 EPS. Sell-side analysts expect that Avantor, Inc. will post 1.06 EPS for the current year.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.